Novavax NVAX Cost reimbursements — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Novavax's cost reimbursements — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Novavax's cost reimbursements — total revenue?
- Novavax (NVAX) reported cost reimbursements — total revenue of $27.72M in Q1 2026.
- How has Novavax's cost reimbursements — total revenue changed year-over-year?
- Novavax's cost reimbursements — total revenue increased by 146.1% year-over-year, from $11.27M to $27.72M.
- What does cost reimbursements — total revenue mean?
- This metric represents the total revenue recognized from the reimbursement of costs incurred by the company while performing research, development, or manufacturing activities on behalf of third-party partners or government entities. It reflects the financial recovery of operational expenditures associated with collaborative agreements or grant-funded programs. This revenue stream is indicative of the company's ability to leverage external funding to offset the financial burden of its clinical and commercial development pipeline.